Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

SERA PROGNOSTICS, INC. Director's Dealing 2021

Jul 22, 2021

34084_dirs_2021-07-21_e0e657be-be68-49cf-8589-40cfda0862a7.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: SERA PROGNOSTICS, INC. (SERA)
CIK: 0001534969
Period of Report: 2021-07-19

Reporting Person: CRITCHFIELD GREGORY C (Director, Chief Executive Officer)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2021-07-19 Class A Common Stock C 34383 Acquired 744355 Direct
2021-07-19 Class A Common Stock C 5253 Acquired 749608 Direct
2021-07-19 Class A Common Stock C 11880 Acquired 761488 Direct
2021-07-19 Class A Common Stock C 4727 Acquired 766215 Direct
2021-07-19 Class A Common Stock C 28730 Acquired 794945 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2021-07-19 Series A-2 Preferred Stock $ C 34383 Disposed Class A Common Stock (34383) Direct
2021-07-19 Series B-1 Preferred Stock $ C 5253 Disposed Class A Common Stock (5253) Direct
2021-07-19 Series B-2 Preferred Stock $ C 11880 Disposed Class A Common Stock (11880) Direct
2021-07-19 Series C-1 Preferred Stock $ C 4727 Disposed Class A Common Stock (4727) Direct
2021-07-19 Series D Preferred Stock $ C 28730 Disposed Class A Common Stock (28730) Direct

Footnotes

F1: The Issuer's Series A-2 Preferred Stock is convertible at the option of a holder at any time into shares of the Issuer's Class A Common Stock at a conversion price, as adjusted to reflect the Issuer's recent 1-for-0.481 reverse stock split, of $5.20 per share. The Series A-2 Preferred Stock has no expiration date.

F2: Includes 630,832 shares of Class A Common Stock directly held by The Gregory C. Critchfield & Trust. Dr. Critchfield is a Trustee of the Gregory C. Critchfield & Trust. Dr. Critchfield, in such capacity, may be deemed to indriectly beneficially own the securities owned by the trust except to the extent of his pecuniary interest therein, if any.

F3: The Issuer's Series B-1 Preferred Stock is convertible at the option of a holder at any time into shares of the Issuer's Class A Common Stock at a conversion price, as adjusted to reflect the Issuer's recent 1-for-0.481 reverse stock split, of $5.20 per share. The Series B-1 Preferred Stock has no expiration date.

F4: The Issuer's Series B-2 Preferred Stock is convertible at the option of a holder at any time into shares of the Issuer's Class A Common Stock at a conversion price, as adjusted to reflect the Issuer's recent 1-for-0.481 reverse stock split, of $8.32 per share. The Series B-2 Preferred Stock has no expiration date.

F5: The Issuer's Series C-1 Preferred Stock is convertible at the option of a holder at any time into shares of the Issuer's Class A Common Stock at a conversion price, as adjusted to reflect the Issuer's recent 1-for-0.481 reverse stock split, of $12.37 per share. The Series C-1 Preferred Stock has no expiration date.

F6: The Issuer's Series D Preferred Stock is convertible at the option of a holder at any time into shares of the Issuer's Class A Common Stock at a conversion price, as adjusted to reflect the Issuer's recent 1-for-0.481 reverse stock split, of $9.02 per share. The Series D Preferred Stock has no expiration date.

F7: The shares of preferred stock automatically converted into the Issuer's Class A Common Stock in accordance with the Issuer's Restated Certificate of Incorporation, as amended, immediately upon completion of the Issuer's initial public offering, which became effective on July 19, 2021.